EXPRESSION OF GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE IN THE TUMOR TISSUE OF BREAST CANCERS

E.A. Shliakhtunou
Vitebsk State Medical University, Vitebsk, Belarus

**ABSTRACT** — Tumor proliferation of cancer cells requires a high intake of oxygen by angiogenesis. Deep cancer cells suffer from asphyxia and meet their energy needs through the enzymes of glycolysis. The antiangiogenesis approach has been recognized for therapeutic purposes, but the deep cancers, difficult to reach by this therapy, could be targeted by inhibiting an enzyme of the glycolytic cycle. Our work focused on the study of the expression of GAPDH, a key enzyme of glycolysis, in breast tumor, for two approaches: Fundamental and targeted therapeutics. 63 samples, taken at the Anatomopathology laboratory of the Vitebsk State Medical University, were examined histologically and immunohistochemically, demonstrating the expression and cellular localization of GAPDH. Breast organ have shown an overexpression of GAPDH in tumor tissues. At the cellular level, the localization of GAPDH in cancer tissue is diffuse but mostly nuclear whereas it remains focused at the membrane and/or the cytoplasm in benign tumor tissues. From these results we could assume that GAPDH is involved in the cancer process and draws attention to a possible new nuclear role that could be either specific to one form or different isoforms of GAPDH enzyme.

**KEYWORDS** — Cancer; GAPDH; Immunohistochemistry; Expression; Isoforms

**INTRODUCTION**

According to WHO, cancer is a disease that affects over 10 million people worldwide. Due to its potential severity, the disease affects the quality of the patient’s life. It seems to affect people at random and the treatment remains heavy expensive. Usually, Cancer is presented as a tumor mass which is the culmination of a series of transformations that can occur over a period of several years. The understanding of cancer natural history remains unclear/uneasy because of its frequency, complexity, malignity and diversity of signaling pathways and therefore, more difficult to develop new therapeutic strategies.

Oxygen plays a key role in the functioning of healthy and cancer cells. Some studies estimate that the tumor proliferation of cancer cells requires a high intake of oxygen via angiogenesis. In the case of less advanced cancers, some antiangiogenic therapies seek to cause cell degeneration by preventing the proliferation of blood vessels that feed oxygen. However, deep cancer cells escape this therapy, because they suffer from asphyxia and instead rely on the conversion of glucose to energy needs through the enzymes of glycolysis [1]. This is in accordance with the Warburg studies; which demonstrated that tumor cells have an increased rate of glycolysis [2].

The glyceraldehyde-3-phosphate dehydrogenase (GAPDH), is described as a key enzyme of glycolysis. It is considered one of the best characterized glycolytic enzymes at the biochemical and structural level [3, 4].

It catalyzes the oxidative phosphorylation of D-glyceraldehyde-3-phosphate (G3P) to 1.3 diphosphoglyceric acid (1.3 DPG).

In addition to glycolysis, this enzyme is also implicated in the Krebs cycle and pentose phosphate pathway, being in this way involved in all three lanes of central carbon metabolism [5]. GAPDH is a ubiquitous enzyme known among all living beings including the three major evolutionary lineages; Archaeabacteria, Eubacteria and Eukaryotes. It is considered among the best conserved proteins [5, 6].

The native protein is a tetramer with a molecular mass of 140 kDa and 220 kDa depending on the type of GAPDH. Each monomer consists of approximately 330–498 amino acids and has a molecular weight between 35 and 50 kDa. [7].
Human GAPDH gene organization was examined using the selective loss of human chromosomes in human-rodent somatic cell hybrids [8]. The GAPDH gene was localized to chromosome 12 based on its concordant expression with lactate dehydrogenase B (LDH-B), with triosephosphateisomerase (TPI) as well as the lack of such associations with 28 other human enzymes [9].

Apart from its glycolytic function, phosphorylating GAPDH presents a variety of activities depending on its membrane, cytoplasmic or nuclear localization [10]. Having in addition to its catalytic function other roles in physiological processes, a series of studies has shown the involvement of GAPDH in initiating the cascade of hepatocyte apoptosis [11].

Further investigations have shown that cancers have a metabolism based on glycolysis, comprising the conversion of glucose into pyruvate and in the case of oxidative stress; the accumulation of errors in the post-translational structure of GAPDH increases the aging process [12].

Recently different teams have examined the expression analysis of GAPDH in tumors and human cancer cell lines. Thereby in Ovarian cancer, GAPDH expression increases mRNA stability of CSF, an important cytokine in tumor progression [13]. In Thyroid cancer, GAPDH undergoes S-nitrosylation to facilitate its trans-location to the nucleus in order to activate the TRAIL (Tumor Necrosis Factor Related Apoptosis Inducing Ligand) [14].

What about the expression of GAPDH in breast cancers, representing an estimated 25% of the cancer deaths in women [15].

**MATERIALS AND METHODS**

**Patients**

63 samples including breast were recruited at the Anatomopathology laboratory of the Vitebsk State Order of Peoples Friendship Medical University from patients for diagnosing, were studied histologically and immunohistochemically. We studied the expression of GAPDH in both malignant (34) and benign (29) lesions.

**Methods, Histological Study**

The Histological study was performed on surgical specimens, collected by the specialist, fixed in formalin, and then routed to the Laboratory of Anatomopathology where they are listed. The samples were then subjected to a macroscopic study and were described by the pathologist. Then they were passed through a series of intermediate liquids in a circulation automaton before being embedded in paraffin to obtain blocks ready to be cut by microtome in order to obtain transparent ultrathin sections with a thickness of about 4 to 5 micrometers. The biofilms were delicately placed on slides previously treated with distilled water and a drop of glycerine albumin that allows the bonding of biofilm on the slide to be stained with hematoxylin eosin (HE).

**Methods, Immunohistochemical Study**

Sections of 5 μm were made from paraffin blocks used for diagnosis. These sections were collected on silanized slides and were dried overnight in a stove at 37° C. They were then deparaffinized in three toluene baths: 5 min (×3). Rehydrated in decreasing degree alcohol baths: Absolute ethanol: 5 min, Absolute ethanol: 5 min, 96° Ethanol: 5 min, 80° Ethanol: 5 min, 70° Ethanol: 5 min. Washed with distilled water: 10 min. Placed in 10% citrate buffer in a water bath preheated to 75° C for 20 minutes to unmask specific antigenic sites. The sections were then left to cool for 15 minutes in the same buffer at room temperature and washed with PBS (Phosphate Buffer Salin) for 5 minutes. The outline of each cut was dried with filter paper and circled with Pap Pen. The endogenous peroxidase activity was inhibited by incubating the sections for 5 minutes in 3% hydrogen peroxide followed by rinsing with two PBS baths for 5 min (×2). Tissue sections were incubated in the presence of skim milk for 5 min then for 45 minutes at room temperature with primary antibody polyclonal anti human GAPDH [17] diluted to 1:50, 1:80, 1:100, 1:1500 and 1:1500 in PBS buffer. After rinsing with PBS, sections were incubated for 30 minutes at room temperature in a humid chamber with secondary antibody linked to peroxidase diluted to 1:1000 in PBS and then rinsed with PBS. Before adding the substrate/chromogenic solution, the slides were rinsed with distilled water and stained with hematoxylin of Mayer. Negative controls were obtained by replacing the primary antibody with buffer. The immunostaining was performed through slides observation at optical microscope in white light using the objectives (×10) and (×40).

**RESULTS AND DISCUSSION**

The immunohistochemical results were used to estimate the expression level of GAPDH and its immunolocalization in different lesions of breast.

We found that the expression level of GAPDH became more intense and diffuse in tumor tissues compared with benign tissue. This applies to the breast tissue (Figures 1–2). These results complement and are consistent with those of Aparecida Corrêa et al. for breast cancer [16]. This result seems to prove the involvement of GAPDH in the tumor process. It is also clear that the localization of GAPDH in the three
organs vary with the degree of tumor differentiation (Table 1). Thus, in breast cancer, it was demonstrated that the expression of GAPDH was dependent on the stage of the disease so that it increased significantly in the most advanced stages. It should be noted that it has cytoplasmic or membrane localization in breast, cervix and prostate benign lesions. Whereas the membrane localization is probably related to its role as a carrier and its ability to bind to the membrane, as described by Sirover [9], the cytoplasmic localization can be related to its pivotal role as glycolytic enzyme [10, 11]. Or it may be related to its role as kinase capable of phosphorylating cytoplasmic proteins [9].

Table 1. Identification of the immunolocalization of GAPDH in breast lesions by immunohistochemical study

<table>
<thead>
<tr>
<th>Lesions</th>
<th>Membrane</th>
<th>Cytoplasmic</th>
<th>Nuclear</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solitary cyst with sore</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Adenosis</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>Fibroadenoma</td>
<td>++</td>
<td>++</td>
<td>−</td>
</tr>
<tr>
<td>Carcinoma</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
</tbody>
</table>

In breast cancer cases, we have found a membrane, cytoplasmic and particularly a nuclear overexpression. This overexpression suggests either its involvement in the cancer process, and therefore, draws attention to a new possible role of GAPDH in carcinogenesis which can be added to those already described or it suggests that GAPDH undergoes regulation in tumor tissue, in relation to carcinogenesis, being involved in other roles independently of its classical glycolytic role [17]. Although GAPDH seems involved in malignant tumor process, until now, there is no certainty about this likely role.

This could help to develop a gene therapy with antisense oligodeoxynucleotides directed against the mRNA isoform (s) in cancer cases involving overexpression of GAPDH.

**Conclusions**

Our study has shown that the in organ Breast GAPDH showed an overexpression in malignant tumor tissues. It has been shown that labeling was essentially nuclear in malignant lesions.

These results suggest GAPDH involvement in cancer process and draw attention to a probable new nuclear role. In addition to other functions already described such as its implication in glycolysis, apoptosis or oxidative stress, GAPDH may be implicated in DNA replication or repair.

Although GAPDH seems to be involved in malignant tumor process, there is no certainty about its specific role in the studied pathologies. Therefore it
would be very interesting to evaluate the expression of the gene encoding this enzyme.

Moreover, it seems important to demonstrate whether the new role of GAPDH remains specific to a single form, or it is related to different isoforms of the enzyme, which can help to develop a gene therapy with antisense oligodeoxynucleotides directed against isoform(s) mRNA(s) in cases of cancer involving overexpression of GAPDH. oligodeoxynucleotides directed against isoform(s) mRNA(s) in cases of cancer involving overexpression of GAPDH.

REFERENCES


The article is devoted to the subjects of basic oncology, and highlights the study of the metabolism of the tumor tissue of breast cancer and identifies new and promising therapeutic approaches for the treatment of this disease. The research was conducted in a careful and objective way and can be recommended for publishing in the medical Journal Archiv Euromedica.

Prof. V.M. Semenov, Vitebsk State Medical University Vitebsk, Belarus